AstraZeneca PLC (LON:AZN) Receives £121.57 Consensus Target Price from Analysts

AstraZeneca PLC (LON:AZN) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is £121.57 ($154.22).

AZN has been the topic of several research analyst reports. Berenberg Bank boosted their price objective on AstraZeneca from £130 ($164.91) to £150 ($190.28) and gave the company a “buy” rating in a report on Friday, June 7th. Barclays reiterated an “overweight” rating and issued a £125 ($158.57) price objective on shares of AstraZeneca in a report on Monday, April 8th. Jefferies Financial Group restated a “hold” rating and set a £113 ($143.35) price target on shares of AstraZeneca in a report on Tuesday, May 21st. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a £110 ($139.54) price target on shares of AstraZeneca in a report on Tuesday, June 18th. Finally, Shore Capital restated a “buy” rating on shares of AstraZeneca in a report on Tuesday, May 21st.

AstraZeneca Price Performance

AZN stock opened at £126.68 ($160.70) on Wednesday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 92.51. The company has a market capitalization of £196.35 billion, a PE ratio of 4,022.44, a P/E/G ratio of 0.97 and a beta of 0.16. AstraZeneca has a 12-month low of GBX 9,461 ($120.02) and a 12-month high of £127.04 ($161.16). The business’s fifty day moving average price is £121.41 and its 200 day moving average price is £110.34.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.